Literature DB >> 25083205

Risks and benefits of (pharmaco)epidemiology.

Lesley Wise1.   

Abstract

Pharmacoepidemiology is a relatively young scientific discipline that has seen tremendous growth in interest over the past two decades. This is partly due to changes in the approval of new drugs, which often now require proactive studies to monitor and extend the knowledge of safety in the postauthorization period. Pharmacoepidemiology studies are observational in nature, in contrast to the randomized controlled trial which is the mainstay of drug development. This means that such studies need careful design and execution in order to maximize the benefits of proactive research in the 'real-life' clinical environment and minimize the risks of false results.

Keywords:  benefit; bias; confounding; pharmaceutical; pharmacoepidemiology; postauthorization; risk

Year:  2011        PMID: 25083205      PMCID: PMC4110815          DOI: 10.1177/2042098611404920

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN: 2042-0986


  9 in total

1.  When are observational studies as credible as randomised trials?

Authors:  Jan P Vandenbroucke
Journal:  Lancet       Date:  2004-05-22       Impact factor: 79.321

2.  Benefits and harms of drug treatments.

Authors:  Jan P Vandenbroucke
Journal:  BMJ       Date:  2004-07-03

3.  Tutorial in biostatistics: the self-controlled case series method.

Authors:  Heather J Whitaker; C Paddy Farrington; Bart Spiessens; Patrick Musonda
Journal:  Stat Med       Date:  2006-05-30       Impact factor: 2.373

4.  'Why me?' versus 'why now?'--differences between operational hypotheses in case-control versus case-crossover studies.

Authors:  Malcolm Maclure
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-08       Impact factor: 2.890

5.  A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.

Authors:  Dean A Fergusson; Paul C Hébert; C David Mazer; Stephen Fremes; Charles MacAdams; John M Murkin; Kevin Teoh; Peter C Duke; Ramiro Arellano; Morris A Blajchman; Jean S Bussières; Dany Côté; Jacek Karski; Raymond Martineau; James A Robblee; Marc Rodger; George Wells; Jennifer Clinch; Roanda Pretorius
Journal:  N Engl J Med       Date:  2008-05-14       Impact factor: 91.245

Review 6.  New approaches to drug safety: a pharmacovigilance tool kit.

Authors:  Lesley Wise; John Parkinson; June Raine; Alasdair Breckenridge
Journal:  Nat Rev Drug Discov       Date:  2009-09-18       Impact factor: 84.694

7.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

8.  Integrating evidence from multiple sources to evaluate post-approval safety: an example of sildenafil citrate and cardiovascular events.

Authors:  Rachel E Sobel; Robert F Reynolds
Journal:  Curr Med Res Opin       Date:  2008-05-27       Impact factor: 2.580

9.  Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database.

Authors:  D Gunnell; D Irvine; L Wise; C Davies; R M Martin
Journal:  BMJ       Date:  2009-10-01
  9 in total
  6 in total

1.  Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort.

Authors:  Steven F G Jeuring; Tim R A van den Heuvel; Limmie Y L Liu; Maurice P Zeegers; Wim H Hameeteman; Mariëlle J L Romberg-Camps; Liekele E Oostenbrug; Ad A M Masclee; Daisy M A E Jonkers; Marieke J Pierik
Journal:  Am J Gastroenterol       Date:  2016-12-06       Impact factor: 10.864

2.  Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications.

Authors:  Arton Baftiu; Cecilie Johannessen Landmark; Ida Rudberg Rusten; Silje Andrea Feet; Svein I Johannessen; Pål G Larsson
Journal:  Eur J Clin Pharmacol       Date:  2016-07-13       Impact factor: 2.953

3.  Machine Learning Prediction of Progression in Forced Expiratory Volume in 1 Second in the COPDGene® Study.

Authors:  Adel Boueiz; Zhonghui Xu; Yale Chang; Aria Masoomi; Andrew Gregory; Sharon M Lutz; Dandi Qiao; James D Crapo; Jennifer G Dy; Edwin K Silverman; Peter J Castaldi
Journal:  Chronic Obstr Pulm Dis       Date:  2022-07-29

Review 4.  Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2).

Authors:  Amos D Korczyn; Steven C Schachter; Martin J Brodie; Sarang S Dalal; Jerome Engel; Alla Guekht; Hrvoje Hecimovic; Karim Jerbi; Andres M Kanner; Cecilie Johannessen Landmark; Pavel Mares; Petr Marusic; Stefano Meletti; Marco Mula; Philip N Patsalos; Markus Reuber; Philippe Ryvlin; Klára Štillová; Roberto Tuchman; Ivan Rektor
Journal:  Epilepsy Behav       Date:  2013-06-10       Impact factor: 2.937

5.  Amoxicillin Utilization Pattern at Governmental Hospitals in Eastern Ethiopia.

Authors:  Tigist Gashaw; Mekonnen Sisay; Tewodros Tesfa; Yohannes Baye; Firehiwot Amare
Journal:  Infect Drug Resist       Date:  2021-01-20       Impact factor: 4.003

6.  Medication use and risk of amyotrophic lateral sclerosis-a systematic review.

Authors:  Can Cui; Jiangwei Sun; Kyla A McKay; Caroline Ingre; Fang Fang
Journal:  BMC Med       Date:  2022-08-05       Impact factor: 11.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.